Floatz logo

GANCOTAMAB

Neurologically Stable

Pamela Munstermonoclonal_antibodyEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Neurologically Stable cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Pamela Munster
Early Phase 1C

Same molecule, other indications

GANCOTAMAB is also rated in:

HER2 positive breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
breast cancerDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →